TELIGENT, INC. (NASDAQ:TLGT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.
|
Submission of Matters to a Vote of Security Holders. |
(a)On May 18, 2017, Teligent, Inc. (the Company)
held its 2017 Annual Meeting of Stockholders (the Annual
Meeting). At the Annual Meeting, the holders of
48,586,331 shares of the Companys common stock were present in
person or represented by proxy, which represents 91.28% of the
total shares of outstanding common stock entitled to vote as of
the record date of March 30, 2017.
(b)The following actions were taken in the Annual Meeting:
| (1) |
The following six nominees were reelected to serve on the Companys Board of Directors (the Board) until the Companys 2018 annual meeting of stockholders or until their respective successors have been elected and qualified, or until their earlier resignation or removal: |
| Name of Director Nominees | Votes For | Votes Withheld | Broker Non-Vote |
| Jason Grenfell-Gardner | 30,579,727 | 420,759 | 17,585,845 |
| Bhaskar Chaudhuri | 30,090,097 | 910,389 | 17,585,845 |
| Steven Koehler | 30,125,654 | 874,832 | 17,585,845 |
| James C. Gale | 30,121,831 | 878,655 | 17,585,845 |
| John Celentano | 30,092,227 | 908,259 | 17,585,845 |
| Carole S. Ben-Maimon | 30,124,355 | 876,131 | 17,585,845 |
| (2) |
The selection of EisnerAmper LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2017, was ratified, based on the following votes: |
| Votes For | Votes Against | Abstentions | Broker Non-Vote |
| 48,176,656 | 81,904 | 327,771 |
| (3) |
The compensation of the Companys named executive officers, as disclosed in our proxy statement, was approved by an advisory vote, based on the following votes: |
| Votes For | Votes Against | Abstentions | Broker Non-Vote |
| 28,341,814 | 2,223,951 | 434,721 | 17,585,845 |
About TELIGENT, INC. (NASDAQ:TLGT)
Teligent, Inc., formerly IGI Laboratories, Inc., is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It has two platforms: developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its current contract manufacturing and formulation services business. Its pipeline includes over 30 Abbreviated New Drug Applications filed with the United States Food and Drug Administration for additional pharmaceutical products. It holds additional over 40 product candidates at various stages of its development pipeline, 10 of which are on stability testing. TELIGENT, INC. (NASDAQ:TLGT) Recent Trading Information
TELIGENT, INC. (NASDAQ:TLGT) closed its last trading session down -0.03 at 8.64 with 130,149 shares trading hands.